

September 5, 2013



XOMA to Present at the Morgan Stanley Healthcare Conference

BERKELEY, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, MD, the Company's Senior Vice President, Research and Development and Chief Medical Officer, is scheduled to present at the Morgan Stanley Healthcare Conference at 11:45 a.m., on September 11, 2013, at the Grand Hyatt Hotel in New York City.

A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at <http://investors.xoma.com/events.cfm>. An archived version of the webcast will be available via replay for 30 days following the presentation.

About XOMA Corporation

XOMA's portfolio of innovative product candidates is the result of the Company's focus on allosteric modulation, which offers opportunities to develop new classes of therapeutic antibodies with the potential to treat a wide range of human diseases. XOMA is developing its lead product gevokizumab (IL-1 beta modulating antibody) with SERVIER through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. XOMA's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major effect on the treatment of diabetes.

More detailed information can be found at www.xoma.com.

CONTACT: Company and Investor Contacts:

Ashleigh Barreto
510-204-7482
barreto@xoma.com

Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com

Media Contact:
Canale Communications
Carolyn Hawley
619-849-5375
carolyn@canalecomm.com

Source: XOMA Corporation